Frontline Sequential Allogeneic Stem Cell Transplantation for Newly Diagnosed Acute Myeloid Leukemia with 3q26.2/Mecom Rearrangement
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-208585
Abstract: BACKGROUND Acute myeloid leukemia with 3q26.2/MECOM rearrangement (MECOMr AML) is a rare entity with very poor prognosis due to the low efficacy of standard treatments. Allogeneic stem cell transplantation (alloSCT) remains the only curative or… read more here.
Keywords: allosct; stem cell; flag ida; ida ven ... See more keywords
High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1666
Abstract: Background: Despite significant advances in treatment of AML over the past decade, long-term survival remains poor. The addition of venetoclax (Ven) to intensive chemotherapy backbones has been evaluated in multiple early-phase clinical trials demonstrating high… read more here.
Keywords: flag ida; risk; response; ida ven ... See more keywords